Shares of Compass Therapeutics (CMPX) have skyrocketed 108.3% in a month after the company announced updates regarding its pipeline development programs and current cash position. The phenomenal stock price rally underscores positive investors’ expectations regarding the pipeline potential of the clinical-stage, oncology-focused biotech company.CMPX’s Lead Pipeline ProgramCompass Therapeutics’ lead therapeutic candidate, tovecimig (CTX-009), is currently being evaluated in a phase II/III study in combinatio ...